Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744939 · ClinicalTrials.gov registry record
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 168
- Enrollment target
NCT00744939 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 168 participants.
The verdict
NCT00744939 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 168 participants
- Enrollment target
Study Summary
Assess potential risk for NSF in subjects with renal impairment (moderate) post magnevist injection. Subjects will be screened within 48 hours of previously scheduled MRI, those meeting the enrollment criteria will be enrolled prior to MRI and followed for 2 years post MRI with visits occuring at 1yr and 2 yr timepoints, in addition follow-up phone calls conducted at 1, 3, 6 and 18 months to assess for skin changes suggestive of NSF.
Interventions
- DRUG Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2008-11 |
| Est. Completion | 2013-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00744939
The ClinicalTrials.gov registry entry for NCT00744939 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gadopentetate dimeglumine (Magnevist, BAY86-4882) is the first listed.
NCT00744939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00744939 about?
NCT00744939 is a clinical study titled "Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist". Assess potential risk for NSF in subjects with renal impairment (moderate) post magnevist injection. Subjects will be screened within 48 hours of previously scheduled MRI, those meeting the enrollment criteria will be enrolled prior to MRI and followed for 2 years post MRI with visits occuring at 1y...
What is the current status of trial NCT00744939?
This trial is currently completed. The enrollment target is 168 participants. The study started on 2008-11. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00744939?
The interventions under investigation include: Gadopentetate dimeglumine (Magnevist, BAY86-4882) (DRUG).
Who is sponsoring clinical trial NCT00744939?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.